Enanta is using its robust, chemistry-driven approach and drug discovery capabilities to become a leader in the discovery and development of small molecule drugs for the treatment of viral infections and liver diseases. Enanta's research and development efforts have produced clinical candidates for the following disease targets: respiratory syncytial virus (RSV), non-alcoholic steatohepatitis (NASH) and hepatitis B virus (HBV). Enanta is also conducting research in human metapneumovirus (hMPV) and emerging coronaviruses, including SARS-CoV-2.
Company profile
Ticker
ENTA
Exchange
Website
CEO
Jay Luly
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
Enanta Pharmaceuticals Security Corporation ...
ENTA stock data
Analyst ratings and price targets
Current price
Average target
$53.00
Low target
$49.00
High target
$56.00
SVB Leerink
Maintains
$49.00
HC Wainwright & Co.
Initiated
$56.00
RBC Capital
Maintains
$54.00
Latest filings (excl ownership)
DEFA14A
Additional proxy soliciting materials
20 Jan 23
DEF 14A
Definitive proxy
20 Jan 23
10-K
2022 FY
Annual report
23 Nov 22
8-K
Results of Operations and Financial Condition
21 Nov 22
8-K
Entry into a Material Definitive Agreement
26 Aug 22
424B5
Prospectus supplement for primary offering
26 Aug 22
10-Q
2022 Q3
Quarterly report
8 Aug 22
8-K
Results of Operations and Financial Condition
8 Aug 22
8-K
Other Events
22 Jun 22
8-K
Entry into a Material Definitive Agreement
17 May 22
Transcripts
ENTA
Earnings call transcript
2022 Q4
21 Nov 22
ENTA
Earnings call transcript
2022 Q3
9 Aug 22
ENTA
Earnings call transcript
2022 Q2
10 May 22
ENTA
Earnings call transcript
2022 Q1
9 Feb 22
ENTA
Earnings call transcript
2021 Q4
23 Nov 21
ENTA
Earnings call transcript
2021 Q3
8 Aug 21
ENTA
Earnings call transcript
2021 Q2
10 May 21
ENTA
Earnings call transcript
2021 Q1
9 Feb 21
ENTA
Earnings call transcript
2020 Q4
23 Nov 20
ENTA
Earnings call transcript
2020 Q3
5 Aug 20
Financial summary
| Quarter (USD) | Sep 22 | Jun 22 | Mar 22 | Dec 21 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Annual (USD) | Sep 22 | Sep 21 | Sep 20 | Sep 19 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
|---|---|---|---|---|---|---|
| Cash on hand (at last report) | 43.99 mm | 43.99 mm | 43.99 mm | 43.99 mm | 43.99 mm | 43.99 mm |
| Cash burn (monthly) | (no burn) | 1.10 mm | 9.02 mm | 10.32 mm | 5.18 mm | 7.07 mm |
| Cash used (since last report) | n/a | 4.44 mm | 36.34 mm | 41.60 mm | 20.87 mm | 28.48 mm |
| Cash remaining | n/a | 39.56 mm | 7.65 mm | 2.39 mm | 23.12 mm | 15.51 mm |
| Runway (months of cash) | n/a | 35.9 | 0.8 | 0.2 | 4.5 | 2.2 |
Institutional ownership, Q3 2022
86.5% owned by funds/institutions
| 13F holders | Current |
|---|---|
| Total holders | 155 |
| Opened positions | 20 |
| Closed positions | 17 |
| Increased positions | 62 |
| Reduced positions | 46 |
| 13F shares | Current |
|---|---|
| Total value | 936.83 mm |
| Total shares | 18.06 mm |
| Total puts | 21.90 k |
| Total calls | 189.60 k |
| Total put/call ratio | 0.1 |
| Largest owners | Shares | Value |
|---|---|---|
| BLK Blackrock | 3.62 mm | $187.86 mm |
| Armistice Capital | 2.07 mm | $107.48 mm |
| Farallon Capital Management | 1.55 mm | $80.40 mm |
| Vanguard | 1.48 mm | $76.61 mm |
| NTRS Northern Trust | 964.41 k | $50.02 mm |
| Ra Capital Management | 896.72 k | $46.51 mm |
| Krensavage Asset Management | 589.36 k | $30.57 mm |
| Dimensional Fund Advisors | 509.88 k | $26.45 mm |
| Fairmount Funds Management | 469.26 k | $24.34 mm |
| Renaissance Technologies | 468.00 k | $24.28 mm |
Recent insider trades
| Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|---|
| 9 Jan 23 | Mellett Paul J | Common Stock | Option exercise | Acquire M | No | No | 14.18 | 2,812 | 39.87 k | 88,463 |
| 9 Jan 23 | Mellett Paul J | Stock Option Common Stock | Option exercise | Dispose M | No | No | 14.18 | 2,812 | 39.87 k | 0 |
| 19 Dec 22 | Luly Jay R. | Common Stock | Option exercise | Acquire M | No | No | 27.58 | 14,500 | 399.91 k | 788,305 |
| 19 Dec 22 | Luly Jay R. | Stock Option Common Stock | Option exercise | Dispose M | No | No | 27.58 | 14,500 | 399.91 k | 55,500 |
| 19 Dec 22 | Mellett Paul J | Common Stock | Option exercise | Acquire M | No | No | 14.18 | 4,148 | 58.82 k | 85,651 |
| 19 Dec 22 | Mellett Paul J | Stock Option Common Stock | Option exercise | Dispose M | No | No | 14.18 | 4,148 | 58.82 k | 0 |
| 16 Dec 22 | Luly Jay R. | Common Stock | Sell | Dispose S | No | Yes | 45.49 | 13,603 | 618.80 k | 773,805 |
| 16 Dec 22 | Luly Jay R. | Common Stock | Sell | Dispose S | No | Yes | 44.54 | 8,597 | 382.91 k | 787,408 |
| 16 Dec 22 | Luly Jay R. | Common Stock | Sell | Dispose S | No | Yes | 43.59 | 7,800 | 340.00 k | 796,005 |
| 16 Dec 22 | Luly Jay R. | Common Stock | Option exercise | Acquire M | No | No | 14 | 13,851 | 193.91 k | 803,805 |
News
SVB Leerink Maintains Market Perform on Enanta Pharma, Lowers Price Target to $49
27 Jan 23
HC Wainwright & Co. Initiates Coverage On Enanta Pharmaceuticals with Buy Rating, Announces Price Target of $56
9 Dec 22
RBC Capital Maintains Sector Perform on Enanta Pharmaceuticals, Lowers Price Target to $54
22 Nov 22
Enanta Pharmaceuticals Q4 EPS $(1.27) Beats $(1.35) Estimate, Sales $20.32M Miss $22.86M Estimate
21 Nov 22
Earnings Scheduled For November 21, 2022
21 Nov 22
Press releases
Enanta Pharmaceuticals to Provide Updates on its Research and Development Programs and 2023 Outlook at the 41st Annual J.P. Morgan Healthcare Conference
6 Jan 23
Enanta Pharmaceuticals to Present at the 41st Annual J.P. Morgan Healthcare Conference
3 Jan 23
Enanta Pharmaceuticals to Participate in Two Investor Conferences in November
22 Nov 22
Enanta Pharmaceuticals Reports Financial Results for its Fiscal Fourth Quarter and Year Ended September 30, 2022 With Webcast and Conference Call Today at 4:30 p.m. ET
21 Nov 22
Enanta Pharmaceuticals Initiates SPRINT, a Phase 2 Clinical Trial of EDP-235, its Oral, Direct-Acting Antiviral Protease Inhibitor Specifically Designed for the Treatment of COVID-19
9 Nov 22